Behzad Hajari
@BehzadHajari
Followers
317
Following
3K
Media
15
Statuses
332
Sydney, Australia
Joined October 2016
1/2 Recognise the achievements and uplift an emerging leader working in the #BBV, #STI, or sexual and reproductive health sector with the 2024 Levinia Crooks Emerging Leader Award. Nominate an early-to-mid career professional now: https://t.co/I9bqVh050C
1
5
7
Can you help us? We are looking for data for our global #prison review examining #bloodborne virus infections, drug use and harm reduction services among #incarcerated people. 📥 Please get in touch with us at global.reviews@unsw.edu.au
0
5
3
Join #INHSUEMCR & @CHERISHresearch for a webinar with @ali_jalali_ & @ShashiKapadiaMD. Learn: ➡️Purpose & approach to economic evaluations ➡️Best practices for determining intervention costs ➡️ Approaches to estimating cost-effectiveness Register: https://t.co/2oGtfLZdY3
0
11
18
Interested in #HCV elimination, and in particular the role of reinfection? read more about it in this paper! Very happy to have been able to contribute to this work with such amazing colleagues 🤓
Positive prospects for #HCV elimination efforts. Multinational study shows HCV reinfection among people with #HIV declined by 28% following the introduction of HCV direct-acting antivirals. @rsacksdavis @DanielavSanten @MargaretHellard
https://t.co/o28KyqwfU8
0
2
8
Great to see this paper in press @LancetGastroHep Amazing leadership from Alison Marshall @KirbyInstitute to pull together this network. Thanks to our global collaborators, including John Ward & Lindsey Hiebert-Suwondo @GlobalHep, @JVLazarus, Andrew Scheibe, & Peter Vickerman
An estimated 57 million people are living with chronic hepatitis C virus (#HCV) infection worldwide. Of 209 total countries & jurisdictions, new Kirby study published in @LancetGastroHep retrieved data from 160 (77%) Read full study here: https://t.co/S7SREzaf5G
0
7
28
Amazing work - massive congrats Hep B PAST team 🎉🎉🎉
JUST PUBLISHED | A new study in @PLOSONE has evaluated the ‘Managing Hepatitis B’ course for the Aboriginal health workforce. It is culturally safe, acceptable & contributes to a significant knowledge improvement in #hepatitisB. Read more: https://t.co/ImTQXFL5eA
0
1
4
Globally, only 49% of people who inject drugs were tested for HIV & 47% for hepatitis C. Study by @KirbyInstitute @NDARCNEWS in @LancetGH showed low testing & treatment uptake in this population in most countries. Strategies to improve access are required: https://t.co/VBUIUXiSMI
0
4
10
Our new paper - open access! Views of key informants on evidence and targets to achieve hepatitis C elimination goals in Australia @LiseLafferty @JoanneBryant14 Jake Rance https://t.co/egL0cMBOUE
onlinelibrary.wiley.com
Enumeration of disease is a key management tool. Setting of targets, like for hepatitis C elimination, have deep meaning and effect. We use the case of elimination in New South Wales (NSW), Austral...
0
6
15
Join @BehzadHajari at #INHSU2023 for a presentation on "Global, regional, and country-level coverage of testing and treatment for #HIV and #HCV infection among people who inject drugs: a systematic review." Plenary abstract speakers now announced: https://t.co/t5pcEP0ynn
0
3
13
🌟 We're proud to present our 2022 Annual Report. 🌟 In 2022, our team of passionate researchers contributed significant, impactful discoveries to improve health and save lives. Read the report now: https://t.co/0NVhtzsF8w
1
6
9
Our study @KirbyInstitute @UNSWMedicine demonstrated that 9% of people with #HCV in 🇦🇺 discontinued therapy (6% in 2016 to 15% in 2021). This📈corresponds to expanding therapy to more marginalized people & highlights needs for access to adherence support & retreatment. @gregdore2
Important: more people are stopping hepatitis C treatment early in a Nationwide study from Australia Some will have been cured by the time they stop. Many may not. It means we need good follow-up, short-duration treatments https://t.co/Ld1D7KZer8
#livertwitter
1
5
21
Join us this coming Tuesday to hear the fascinating history of hepatitis A, B and C from Dr Michelle Bootcov @mishtory 📅 1pm AEST, Tue 2 May | In-person and online | Free 🎫 Registrations essential: https://t.co/1hMGHGndzN 🗣️ Event page: https://t.co/m6vetIQpSv
0
2
2
Latest global estimates on HIV, HCV Ab/RNA testing coverage among people who inject drugs presented by @BehzadHajari #HR23
0
3
9
New global data on #HCV and #HIV testing/treatment among PWID presented by @BehzadHajari @KirbyInstitute from study in collaboration with @NDARCNEWS at #HR23 @HRInews. Demonstrates continued low uptake of HCV/HIV testing/treatment globally. Interventions needed to enhance uptake.
0
13
27
Among people who inject drugs globally, an estimated 15% are living with #HIV and 39% are living with #HCV, @jasongrebely presented in the @HRInews #HR23
@KirbyInstitute @NDARCNEWS
0
4
19
WEBINAR: Hear from authors of top-ranked research papers from #INHSUPrisons2022 Bibliography 📣 Speakers @jack_stone22, Timothy Papaluca @StVincentsMelb, Joanne Carson @KirbyInstitute 📣 Moderators Nadine Kronfli @mcgillu @Juliasheehan11 @HepatitisCTrust
https://t.co/t5EuEUxXP4
0
5
8
Proud of our team for publishing 2 systematic reviews in the Lancet Glob Health on the prevalence of injecting drug use and the coverage of harm reduction interventions for PWID https://t.co/fHEd8Ue3RB
https://t.co/81nRRwE9Bq
thelancet.com
IDU is being identified in a growing number of countries and territories that comprise more than 99% of the global population. IDU-related health harms are common, and people who inject drugs...
1
11
29
Are you an ECR at @UNSWMedicine? Med ECAN have limited paid spots for @StatsCentralAus short courses in 2023! Email your CV and Z-ID to medecan@unsw.edu.au by 1st March for a spot in the upcoming Sample Size and Power Calculations course
unsw.edu.au
Stats Central is a team of consultants focused on building the statistical capacity of UNSW researchers and HDRs. We run professional development workshops, build relationships that facilitate...
0
2
3
Applications open now for the David Cooper Scholarship! 🔬 4yr PhD for candidates in infectious diseases 📈 career development fund, up to $10k/year 🧑💼 research training + career development program 🤝 6m internship with academic unit/industry partner https://t.co/mxszGZ7XDL
0
3
8
In Australia, among 95,272 people with #hepC receiving DAA therapy by end of 2021, 7% were retreated. 52% of retreatment was for reinfection; 48% for treatment failure. Post-treatment #hepC care is essential for people at risk of reinfection. 📕Read more: https://t.co/XsoUkXInnl
1
2
6